• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

    8/29/22 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email

    - Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials -

    WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Dr. Bibbiani brings more than two decades of experience across development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD).

    "We are excited to welcome Francesco to Dyne's development team at this important moment for our company, as our co-lead programs enter global clinical trials," said Wildon Farwell, M.D., MPH, chief medical officer of Dyne. "Francesco brings a breadth of global drug development experience including designing studies, operationalizing clinical trials and shaping regulatory strategy, that ultimately led to approval, making him an invaluable asset to the company as we advance our investigational therapies for people living with serious muscle diseases."

    Dr. Bibbiani joins Dyne from Ultragenyx Pharmaceutical Inc., where he served as vice president of global clinical development and oversaw all stages of the development for neuromuscular and neurology product candidates, providing strategic direction and technical leadership to the clinical development team, including for the company's gene therapy program in DMD. While at Ultragenyx, he was also a member of the DMD Gene Therapy Working Group, comprised of leading experts from the industry and academia collaborating to optimize and provide guidelines for gene therapy in DMD. Previously, Dr. Bibbiani was the vice president of clinical development for PTC Therapeutics, Inc., overseeing multiple clinical trials in DMD and lifecycle management for all products in its neuromuscular portfolio. Prior to PTC Therapeutics he held several roles at Eisai, Inc. as a project and clinical lead, overseeing global clinical development plans and leading multiple New Drug Applications. He received his M.D. and board-certification in neurology from the University of Pisa, Italy. Following that, he completed his fellowship at the National Institutes of Health in Experimental Therapeutics.

    "Having spent many years deeply involved in rare muscle disease drug development, I know first hand the urgent need for new therapeutics. Dyne's FORCE™ platform is an exciting, novel approach leveraging receptor-mediated delivery to target muscle tissue and, ultimately, to potentially modify disease. With robust preclinical data across multiple programs and engagement with community members and other key stakeholders, Dyne is well positioned to execute in the clinic. I look forward to working with the Dyne team, as they are both innovative and passionate about developing therapeutics that have the potential to transform the lives of people with genetically driven muscle diseases," said Dr. Bibbiani.

    About Dyne Therapeutics

    Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

    Forward-Looking Statements



    This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, and the anticipated timelines for the DYNE-251 and DYNE-101 trials, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to initiate and enroll patients in clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether Dyne's cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties associated with the impact of the COVID-19 pandemic on Dyne's business and operations; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.

    Contacts:

    Investors:

    Dyne Therapeutics

    Amy Reilly

    [email protected]

    857-341-1203



    Media:

    Dyne Therapeutics

    Stacy Nartker

    [email protected]

    781-317-1938



    Primary Logo

    Get the next $DYN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    3/7/2025$50.00Sector Outperform
    Scotiabank
    12/13/2024$46.00Outperform
    Robert W. Baird
    11/26/2024$45.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Cox John sold $54,201 worth of shares (4,060 units at $13.35), decreasing direct ownership by 3% to 142,179 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:07:07 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Kerr Douglas sold $17,916 worth of shares (1,342 units at $13.35), decreasing direct ownership by 1% to 92,815 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:05:18 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Friedl-Naderer Johanna sold $1,949 worth of shares (146 units at $13.35), decreasing direct ownership by 0.15% to 95,911 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:03:04 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

      WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditi

      6/30/25 9:45:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Proposed Public Offering of Common Stock

      WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $200,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for

      6/30/25 4:05:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

      - $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction strengthens the company's balance sheet as it advances DYNE-101 and DYNE-251

      6/30/25 4:01:00 PM ET
      $DYN
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance